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INTRODUCTION
Atherosclerotic plaque development and progression are
associated with vascular inflammation, endothelial dysfunc-
tion, and platelet activation (1). Inflammatory mediators,
such as C-reactive protein (CRP) and oxidized low-density
lipoprotein (oxLDL), can trigger platelet activation and
subsequent thrombus formation (2). In turn, activated
platelets secrete cytokines, recruit monocytes, and release
soluble CD40 ligand (sCD40L), which mediate vascular
inflammation (3). An important determinant of endothelial
dysfunction in patients with coronary artery disease (CAD)
is the reduced number of endothelial progenitor cells (EPCs)
(4). Interestingly, EPCs can inhibit platelet activation, while
activated platelets modulate EPC proliferation (5).
Aspirin is widely used in the prevention of complications
related to CAD. However, the mechanisms that promote
high residual platelet reactivity (RPR) in aspirin-treated
patients are still under debate (6,7). Because inflammation
and endothelial dysfunction may possibly contribute to
platelet activation and RPR, we sought to compare
inflammatory markers and EPC levels between stable
CAD patients treated with aspirin with and without RPR.
METHODS
Study design. This was a substudy of a randomized trial
testing lipid-lowering drugs that was performed from July
2006 to January 2009 in a single tertiary specialized cardio-
logy hospital (ClinicalTrials.gov: NCT00474123). Details of the
protocol have been published previously (8). In brief, all of the
patients (n=83) met the following inclusion criteria:
angiographically documented CAD, simvastatin treatment,
and age ,80 years. The exclusion criteria were the following:
myocardial infarction or revascularization ,3 months, ven-
tricular systolic dysfunction, warfarin treatment, malignancy,
inflammatory diseases, and renal/liver dysfunction.
Of the original 83 patients, 63 were on aspirin treatment
(100 mg/day), presented complete data for hsCRP, sCD40L,
oxLDL, and circulating EPCs, and were included in the
present study. No patients were treated with clopidogrel
within the four weeks before enrollment. Platelet aggrega-
tion was measured by the platelet function analyzer (PFA)-
100 closure time (CT). Patients with a CT #150 seconds (sec)
were considered as having RPR (9).
We compared baseline characteristics, inflammatory
levels, and EPC counts between patients with and without
RPR. This study was approved by the institutional research
committee. All of the subjects gave written informed
consent.
Platelet aggregation using the PFA-100 assay. Samples
were collected in 3.2% sodium citrate (buffered, pH 5.5,
Vacutainer, Becton Dickinson, UK) for platelet function
tests. Platelet function was measured with the PFA-100
(epinephrine) point-of-care assay (Dade-Behring, Deerfield,
IL, USA). We defined the upper normal limit for PFA-100
CT as 150 sec, in agreement with previous studies and the
manufacturer’s protocol recommendation (9).
hsCRP, sCD40L, and oxLDL. Serum hsCRP was assessed
with a latex microparticle-enhanced immunoturbidimetric
assay (BN II analyzer, Dade Behring, Deerfield, IL, USA).
The minimal detectable concentration of hsCRP was
0.2 mg/L. For the other markers, commercial ELISAs
detecting sCD40L (R&D Systems, Minneapolis, MN, USA)
and oxLDL (Mercodia, Winston Salem, NC, USA) were
used. The detection limits of the ELISAs were as follows:
sCD40L 15.6 pg/mL (intra-assay variability not available);
oxLDL, 0.3 U/L (intra-assay variability 6.1%).
Endothelial progenitor cells. The detection of EPCs was
performed as previously described (10). In brief, 100 mL of
mononuclear cells derived from peripheral blood was
immunostained with monoclonal antibodies against human
CD31/FITC, CD3/PE-Cy5, CD19/PE-Cy5, CD34/PE-Cy7,
CD14/APC Cy-7 (BD Pharmingen, UK), VEGFR2/PE (R&D
System,Minneapolis, MN, USA), and the appropriate isotype
control antibodies (BD Pharmingen, UK). EPCs were
negative for CD3, CD19, and CD14 and positive for CD31,
CD34, and VEGFR2.
At least 70,000 events were acquired per tube by flow
cytometry (FACSARIA, BD Biosciences, UK). The analysis
was performed using FACSDIVA software (BD Biosciences,
UK).
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Statistical analysis. Continuous variables were
expressed as the mean (¡ standard deviation [SD]) or
median (25th, 75th percentile). Differences were analyzed
with a 2-sample t test when the distribution was normal;
otherwise, we used the Mann-Whitney U test. The X2 test
was used for categorical variables. A value of P,0.05 was
considered significant. Analyses were performed using
STATA/SE 9.2 (Stata Corp LP, USA). Spearman’s rank test
was performed to assess correlations.
RESULTS
The baseline characteristics, including lipids and meta-
bolic profiles, of the 63 patients are shown in Table 1. The
mean (¡SD) age was 63¡9 years. Forty patients (64%) were
male, and 36 (57%) were classified as having RPR. The
median (25th, 75th) PFA-100 CT was 202 (165, 300) sec in
patients without RPR vs. 101 (86, 120) sec in patients with
RPR (p,0.001). The median (25th, 75th) LDL cholesterol
levels were similar and in the normal range in patients both
without and with RPR (103 [89, 117] vs. 99 [85, 126] mg/dL,
p= 0.99), as were triglycerides (118 [85, 151] vs. 136 [92, 163]
mg/dL, p= 0.86) and hemoglobin A1c (5.9% [5.7%, 6.5%] vs.
6% [5.7%, 6.3%], p= 0.73).
As demonstrated in Figure 1, inflammatory markers and
the circulating levels of EPCs were similar in patients with
and without RPR. Inflammatory marker and EPC levels were
not associated with RPR (sCD40L, hazard ratio [HR] 0.99,
95% confidence interval [CI] 0.99–1.0, p=0.75; oxLDL, HR 1.0,
95% CI 0.99–1.02, p=0.94; hsCRP, HR 1.02, 95% CI 0.89–1.17,
p=0.71; and EPCs, HR 1.03, 95% CI 0.97–1.1, p=0.30).
Additionally, no correlation was noted between PFA-100
and inflammatory markers or EPC values (Figure 2).
DISCUSSION
Our study did not identify an association between
inflammatory markers or circulating EPCs and RPR in
patients with stable CAD treated with low-dose aspirin.
Additionally, no correlation was noted between PFA-100
and inflammatory markers or EPC values.
We evaluated inflammation by measuring the plasma
levels of hsCRP, oxLDL, and sCD40L which are biomarkers
that have traditionally been correlated with atherosclerotic
activity (11–13). Despite the previous use of aspirin, 57% of
our patients presented with RPR. Previous studies have also
reported a high RPR prevalence in patients treated with
aspirin, but RPR may differ depending on the test applied
(14,15). We performed a PFA-100, an assay with high
sensitivity that is extensively used to identify RPR (15,16).
Moreover, RPR detected by PFA-100 may identify patients
with a higher cardiovascular risk (17).
We hypothesized that RPR could be related to inflamma-
tion and endothelial dysfunction. Our hypothesis was
supported by several in vitro studies demonstrating
inflammatory mechanisms activating platelets, which in
turn increase atherothrombotic activity (18). OxLDL can
activate platelets by acting on the scavenger receptor CD36
(19). Similarly, sCD40L can trigger platelet aggregation and
is correlated with plasma P-selectin and urinary thrombox-
ane levels (20,21). Activated platelets can induce the
secretion of chemokines in various cells of the vascular
wall (3). Platelet factor-4 attracts monocytes, promoting
their differentiation into macrophages (22). In addition,
CD40L expressed by activated platelets acts on endothelial
cells, increasing the release of interleukin-8 and monocyte
chemoattractant protein-1 (23).
In contrast, few clinical studies have investigated the
association between inflammation or endothelial dysfunc-
tion and platelet hyper-aggregation. Dotsenko et al. have
demonstrated a correlation between increased platelet
aggregation and hsCRP (24). In patients with acute coronary
syndromes, Gori et al. tested the association between several
inflammatory markers and platelet aggregation and found
an association only with IFN-gamma and IL-4 (25). Two
Table 1 - Baseline patient characteristics according to the PFA-100 CT value.
Patients w/out RPR
PFA-100 CT
.150 sec
(n= 27)
Patients w/RPR
PFA-100 CT
#150 sec
(n= 36) p-value
Men, n (%) 18 (67) 22 (63) 0.76
Mean age, in years (¡ SD) 63.3¡10.2 63.1¡8.92 0.94
Body mass index, kg/m2 (¡ SD) 27.8¡2.7 28.3¡3.5 0.54
Coronary risk factors, n (%)
Diabetes mellitus 11 (44) 19 (53) 0.51
Hypertension 19 (81) 30 (83) 0.85
Habitual smoker 3 (11) 8 (22) 0.25
Concomitant medication, n (%)
ACE inhibitor or AT-1 receptor blocker 23 (86) 33 (93) 0.42
Aspirin 27 (100) 36 (100)
Clopidogrel 0 0
Simvastatin 27 (100) 36 (100)
Metabolic parameters, median (IQR)
TG, mg/dL 118 (85–151) 136 (92–163) 0.86
Total cholesterol, mg/dL 171 (156–195) 172 (157–203) 0.59
LDL-C, mg/dL 103 (89–117) 99 (85–126) 0.99
HDL-C, mg/dL 45 (39–51) 43 (38–48) 0.96
Glucose, mg/dL 102 (90–113) 110 (95–125) 0.13
HbA1c, % 5.9 (5.7–6.5) 6 (5.7–6.3) 0.73
Data are expressed as the mean ¡ SD, median (interquartile range [IQR]), or n (%). RPR, residual platelet reactivity; PFA-100 CT, platelet function
analyzer-100 closure time; ACE, angiotensin-converting enzyme inhibitor; AT, angiotensin; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol;
HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c.
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Figure 1 - The levels of (A) high-sensitivity C-reactive protein (hsCRP), (B) soluble CD40 ligand (sCD40L), (C) oxidized low-density
lipoprotein (oxLDL), and (D) endothelial progenitor cells (EPCs) in patients without and with residual platelet reactivity (RPR). The data
are presented as box plots displaying the mean, 25th and 75th percentiles and the minimum, maximum, and outlying values. In
Figure 1-B, one outlier was excluded.
Figure 2 - Correlations between the platelet function analyzer (PFA)-100 and the levels of (A) high-sensitivity C-reactive protein (hsCRP),
(B) soluble CD40 ligand (sCD40L), (C) oxidized low-density lipoprotein (oxLDL), and (D) endothelial progenitor cells (EPCs).
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small studies have demonstrated a correlation between
sCD40L, CRP, and IL-8 and heightened thrombogenicity
in patients undergoing coronary angioplasty (26,27).
Conversely, in patients with stable CAD, a larger study
did not find an association between circulating sCD40L
levels and RPR (28).
In our study, the EPC levels did not differ between patients
with and without RPR. We found EPC levels comparable to
previous findings in patients with stable CAD (29). EPCs are
reduced in CAD patients and are inhibited by atherosclerotic
inflammatory agents, such as oxLDL and CRP (31,32). The
relationship between EPCs and RPR has been poorly
investigated. Daub et al. demonstrated that oxLDL-activated
platelets may reduce EPC numbers (2). Alternatively,
chemokine stromal cell factor-1, which is derived from
activated platelets, may increase EPC levels (33). Finally,
Abou-Saleh et al. showed that EPCs bind to and inhibit
platelet activation via prostacyclin modulation (5).
Thus, despite previous in vitro evidence linking platelet
activation to atherosclerotic inflammation, when we trans-
lated this assumption to human subjects, we did not find an
association between inflammatory markers or circulating
EPCs and RPR in patients with stable CAD treated with
aspirin.
Study limitations
This was a subgroup analysis of a trial investigating lipid-
lowering agents (8). The sample size and power were
primarily estimated based on the main outcome of the
original trial. However, our main results were corroborated
by the absence of a correlation between PFA-100 CT and
inflammatory markers or EPC values. Additionally, we
used a single platelet function assay; it is possible that our
results may have been different if a different platelet test
had been used.
This investigation demonstrated no association between
inflammatory markers or circulating EPCs and RPR in
patients treated with aspirin. Thus, low-grade inflammation
and endothelial dysfunction do not affect the responsive-
ness to aspirin in patients with stable CAD. Our findings
highlight the importance of better understanding the
underlying mechanism of RPR and the uncertainties
inherent to this field of study.
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